000843818 001__ 843818
000843818 005__ 20210129232656.0
000843818 0247_ $$2doi$$a10.1016/j.ejps.2017.12.005
000843818 0247_ $$2ISSN$$a0928-0987
000843818 0247_ $$2ISSN$$a1879-0720
000843818 0247_ $$2pmid$$apmid:29225107
000843818 0247_ $$2WOS$$aWOS:000424977500011
000843818 0247_ $$2altmetric$$aaltmetric:30325454
000843818 037__ $$aFZJ-2018-01358
000843818 082__ $$a610
000843818 1001_ $$0P:(DE-Juel1)166069$$aSchartmann, Elena$$b0
000843818 245__ $$aComparison of blood-brain barrier penetration efficiencies between linear and cyclic all- d -enantiomeric peptides developed for the treatment of Alzheimer's disease
000843818 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2018
000843818 3367_ $$2DRIVER$$aarticle
000843818 3367_ $$2DataCite$$aOutput Types/Journal article
000843818 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1519109657_5864
000843818 3367_ $$2BibTeX$$aARTICLE
000843818 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000843818 3367_ $$00$$2EndNote$$aJournal Article
000843818 520__ $$aAlzheimer's disease (AD), until now, is an incurable progressive neurodegenerative disease. To target toxic amyloid β oligomers in AD patients' brains and to convert them into non-toxic aggregation-incompetent species, we designed peptides consisting solely of d-enantiomeric amino acid residues. The original lead compound was named D3 and several D3 derivatives were designed to enhance beneficial properties. Here, we compare four d-peptides concerning their efficiencies to pass the blood-brain barrier (BBB). We demonstrate that the d-peptides' concentrations in murine brain directly correlate with concentrations in cerebrospinal fluid. The cyclic d-enantiomeric peptide cRD2D3 is characterized by the highest efficiency to pass the BBB. For in total three cyclic peptides we show that administration of cyclic peptides resulted in up to tenfold higher peak concentrations in brain as compared to their linear equivalents which have partially been characterized before (Jiang et al., 2015; Leithold et al., 2016a). These results suggest that cyclic peptides pass the murine BBB more efficiently than their linear equivalents. cRD2D3's proteolytic stability, oral bioavailability, long duration of action and its favorable brain/plasma ratio reveal that it may become a suitable drug for long-term AD-treatment from a pharmacokinetic point of view.
000843818 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000843818 588__ $$aDataset connected to CrossRef
000843818 7001_ $$0P:(DE-Juel1)165908$$aSchemmert, Sarah$$b1
000843818 7001_ $$0P:(DE-Juel1)162487$$aZiehm, Tamar$$b2
000843818 7001_ $$0P:(DE-HGF)0$$aLeithold, Leonie H. E.$$b3
000843818 7001_ $$0P:(DE-Juel1)145884$$aJiang, Nan$$b4
000843818 7001_ $$0P:(DE-Juel1)131709$$aTusche, Markus$$b5
000843818 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b6
000843818 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b7
000843818 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b8
000843818 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b9$$eCorresponding author$$ufzj
000843818 7001_ $$0P:(DE-Juel1)144347$$aWilluweit, Antje$$b10$$eCorresponding author
000843818 773__ $$0PERI:(DE-600)1483522-8$$a10.1016/j.ejps.2017.12.005$$gVol. 114, p. 93 - 102$$p93 - 102$$tEuropean journal of pharmaceutical sciences$$v114$$x0928-0987$$y2018
000843818 8564_ $$uhttps://juser.fz-juelich.de/record/843818/files/1-s2.0-S0928098717306656-main.pdf$$yRestricted
000843818 8564_ $$uhttps://juser.fz-juelich.de/record/843818/files/1-s2.0-S0928098717306656-main.gif?subformat=icon$$xicon$$yRestricted
000843818 8564_ $$uhttps://juser.fz-juelich.de/record/843818/files/1-s2.0-S0928098717306656-main.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000843818 8564_ $$uhttps://juser.fz-juelich.de/record/843818/files/1-s2.0-S0928098717306656-main.jpg?subformat=icon-180$$xicon-180$$yRestricted
000843818 8564_ $$uhttps://juser.fz-juelich.de/record/843818/files/1-s2.0-S0928098717306656-main.jpg?subformat=icon-640$$xicon-640$$yRestricted
000843818 8564_ $$uhttps://juser.fz-juelich.de/record/843818/files/1-s2.0-S0928098717306656-main.pdf?subformat=pdfa$$xpdfa$$yRestricted
000843818 909CO $$ooai:juser.fz-juelich.de:843818$$pVDB
000843818 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166069$$aForschungszentrum Jülich$$b0$$kFZJ
000843818 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)165908$$aForschungszentrum Jülich$$b1$$kFZJ
000843818 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)162487$$aForschungszentrum Jülich$$b2$$kFZJ
000843818 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145884$$aForschungszentrum Jülich$$b4$$kFZJ
000843818 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131709$$aForschungszentrum Jülich$$b5$$kFZJ
000843818 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b6$$kFZJ
000843818 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b7$$kFZJ
000843818 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b8$$kFZJ
000843818 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b9$$kFZJ
000843818 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)144347$$aForschungszentrum Jülich$$b10$$kFZJ
000843818 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000843818 9141_ $$y2018
000843818 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000843818 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000843818 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000843818 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J PHARM SCI : 2015
000843818 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000843818 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000843818 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000843818 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000843818 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000843818 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000843818 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000843818 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000843818 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000843818 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000843818 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x0
000843818 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie $$x1
000843818 9201_ $$0I:(DE-82)080010_20140620$$kJARA-BRAIN$$lJARA-BRAIN$$x2
000843818 980__ $$ajournal
000843818 980__ $$aVDB
000843818 980__ $$aI:(DE-Juel1)INM-4-20090406
000843818 980__ $$aI:(DE-Juel1)ICS-6-20110106
000843818 980__ $$aI:(DE-82)080010_20140620
000843818 980__ $$aUNRESTRICTED
000843818 981__ $$aI:(DE-Juel1)IBI-7-20200312